Clinical Trial of Safety and Efficacy of Daily Application of Topical Dutasteride in Men With Androgenic Alopecia.

NCT ID: NCT05599243

Last Updated: 2024-09-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 45 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-09-29
• Study Completion Date: 2023-08-11

Brief Summary

Alopecia is a disorder that involves the loss of hair from the body. The causes of hair loss can be multiple, but in all cases this loss causes a lot of discomfort to patients for aesthetic and psychological reasons, especially in the female population.This study is going to focus on the topical use of dutasteride in the treatment of men with androgenic alopecia using a new formulation, as an emulsion, capable of transporting this drug to the different structures of the pilosebaceous unit.

Detailed Description

Alopecia is a disorder that involves the loss of hair from the body. The causes of hair loss can be multiple, but in all cases this loss causes a lot of discomfort to patients for aesthetic and psychological reasons, especially in the female population. This disorder, although more visible in men, is suffered by both men and women. Recent studies show that the stress experienced by patients with alopecia can be similar or greater than that suffered by a more serious or chronic disease. For all these reasons, alopecia can prefer a social problem without a definitive therapeutic solution.This study is going to focus on the topical use of dutasteride in the treatment of men with androgenic alopecia using a new formulation, as an emulsion, capable of transporting this drug to the different structures of the pilosebaceous unit. The lipid nature of the formulation and the droplet size of between 150-300 nm means that the emulsion drops easily penetrate the hair follicle and accumulate in the sebaceous glands of said follicles.

Conditions

Male Androgenetic Alopecia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

experimental drug

0.15% w/w dutasteride topical O/W emulsion.

Group Type: EXPERIMENTAL

Dutasteride

Intervention Type: DRUG

The application will be made locally (spray for topical application on the scalp) Application: 1 mL (6 sprays) once a day. Each 1mL of formulation has approximately 1.5mg of Dutasteride (more precisely it would be 1.4835mg when considering density).

Placebo

vehicle (excipients)

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Vehicle excipient

Interventions

Dutasteride

The application will be made locally (spray for topical application on the scalp) Application: 1 mL (6 sprays) once a day. Each 1mL of formulation has approximately 1.5mg of Dutasteride (more precisely it would be 1.4835mg when considering density).

Intervention Type: DRUG

Placebo

Vehicle excipient

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• • - Males over 18 years of age, diagnosed with Sinclair grades I-IV androgenic alopecia, who are not currently undergoing any hair treatment and have not undergone any in the last 3 months.

• - Understand the purpose of the study and be available for frequent visits to the hospital. Sign the informed consent form.
• - Males with a partner of childbearing age must agree to use a contraceptive method with the partner for the duration of the study.

Exclusion Criteria

• • - Patients with a history of hypersensitivity to the active ingredient, to other 5-alpha reductase inhibitors.

• - Patients with severe hepatic insufficiency.
• - Patients who are currently undergoing capillary treatment or have undergone capillary treatment in the last 3 months.
• - Patients unable to understand the objective of the study or to give informed consent.
• - Patients who, in the opinion of the investigator, present any difficulty or situation that would hinder or contraindicate their participation in this study.
• - Patients with a history of drug addiction and drug addictions.
• - Patients who are participating in another clinical trial.
• - Patients whose partner is pregnant

• Minimum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Oscar Muñoz, MD

Role: PRINCIPAL_INVESTIGATOR

IRYCIS. Hospital Universitario Ramón y Cajal. Madrid, Spain.

Locations

Hospital Ramón y Cajal

Madrid, , Spain

Countries

Spain

Other Identifiers

ALOSTOP

Identifier Type: -

Identifier Source: org_study_id